Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

1/27/2023
BreakingDry EyeRegulation
CDC Urges Patients to Stop Using EzriCare Artificial Tears, Citing Infections
CDC Urges Patients to Stop Using EzriCare Artificial Tears, Citing Infections

The Centers for Disease Control and Prevention (CDC) is urging immediate discontinuation of the use of EzriCare Artificial Tears, an over-the-counter drop for dry eye, after linking various infecti...

1/27/2023
BreakingGlaucomaPharmaRevenueSurgical
2022 Ophthalmic Revenue Roundup for J&J Vision Surgical and Nicox
2022 Ophthalmic Revenue Roundup for J&J Vision Surgical and Nicox

Johnson & Johnson reported Jan. 24 that its full year 2022 global surgical vision revenue was $1.31 billion, a 4.6 percent increase (+9.4 percent cc) over $1.25 billion in 2021. Revenue was up 2.0 ...

1/27/2023
BreakingIOLRegulation
Nidek, Health Officials Issue Safety Warning for EyeCee One IOLs
Nidek, Health Officials Issue Safety Warning for EyeCee One IOLs

Japan-based Nidek has issued a field safety notice for all lots of EyeCee One preloaded and EyeCee One Crystal preloaded intraocular lenses (IOLs). The lenses are distributed by Bausch + Lomb. Nide...

1/27/2023
BreakingRefractiveRegulationSurgical
FTC Orders LCA-Vision to Pay $1.25 Million for Deceptive LASIK Ads
FTC Orders LCA-Vision to Pay $1.25 Million for Deceptive LASIK Ads

The Federal Trade Commission announced Jan. 19 that it had issued an order requiring Ohio-based LCA-Vision, doing business as LasikPlus and Joffe MediCenter, to pay $1.25 million for using deceptiv...

1/27/2023
BreakingClinical TrialGlaucomaSurgical
Iantrek Biostent Procedure Reduces IOP 40 Percent, Study Shows
Iantrek Biostent Procedure Reduces IOP 40 Percent, Study Shows

Iantrek, of White Plains, New York, announced Jan. 23 that its novel biostenting procedure reduced intraocular pressure (IOP) nearly 40 percent in a first-in-human trial of 10 patients with open-an...

1/27/2023
BreakingRegulation
Sun Pharma Receives Warning Letter from US FDA Over Manufacturing Concerns
Sun Pharma Receives Warning Letter from US FDA Over Manufacturing Concerns

Sun Pharmaceutical Industries Limited of India received a warning letter from the US FDA dated Dec. 15, 2022, regarding “significant violations” of Current Good Manufacturing Practice (CGMP) regula...

1/27/2023
BreakingCataractIndustryPharmaRetina
EyePoint Plans to Build Manufacturing Facility in Massachusetts
EyePoint Plans to Build Manufacturing Facility in Massachusetts

EyePoint Pharmaceuticals announced Jan. 23 that it plans to build a 40 thousand-square-foot manufacturing facility in Northbridge, Massachusetts, to support the global manufacturing of Yutiq and it...

1/27/2023
BreakingClinical TrialRegulationRetina
US FDA Gives Green Light to Phase II Trial for Oxular’s Suprachoroidal DME Candidate
US FDA Gives Green Light to Phase II Trial for Oxular’s Suprachoroidal DME Candidate

Oxular Limited, of Oxford, UK, announced Jan. 24 that the US FDA had cleared its investigational new drug application for a Phase II trial of suprachoroidal OXU-001 in diabetic macular edema (DME)....

1/27/2023
BreakingRetinaStudy
Research in Type 1 Diabetes Links Lack of Gut Enzyme with DR Severity
Research in Type 1 Diabetes Links Lack of Gut Enzyme with DR Severity

A new study suggests that the root of diabetic retinopathy (DR) appears to lie in the belly—mainly a leaky small intestine that weakens the barrier between gut bacteria and the blood system. Resear...

1/27/2023
BreakingCornealDealsRetina
Longevity Agrees to Combine with Denali SPAC; Pipeline Includes Ophthalmic Candidates
Longevity Agrees to Combine with Denali SPAC; Pipeline Includes Ophthalmic Candidates

Longevity Biomedical, of Bothell, Washington, reported Jan. 26 that it has agreed to merge with Denali Capital Acquisition Corp., of the Cayman Islands, a publicly traded special purpose acquisitio...

1/24/2023
AcquisitionsDealsNewslettterPharma
2022 in Review: Alcon Makes Big Push into Pharma with Three Ophthalmic Acquisitions
2022 in Review: Alcon Makes Big Push into Pharma with Three Ophthalmic Acquisitions

Three of the 19 ophthalmic acquisitions in 2022 were completed by Alcon; the purchases demonstrate the company’s plan to expand its presence in the ophthalmic pharmaceuti-cals market. In 2022, the ...

1/24/2023
AcquisitionsDealsNewslettter
Ophthalmology Sees Record Number of Acquisitions in 2022; Amounts per Deal are Lower
Ophthalmology Sees Record Number of Acquisitions in 2022; Amounts per Deal are Lower

Ophthalmic deals in 2022 neared $5.6 billion and included 85 transactions. This compares with $8.5 billion in 2021 and $9.3 billion in 2020. Mergers and acquisitions totaled $1.9 billion; venture c...

Past News Stories

1/24/2023
EmergingNewsletterPharmaRetina
Interest in Ophthalmic Market Grew in 2022 with Boom in Emerging Companies
Interest in Ophthalmic Market Grew in 2022 with Boom in Emerging Companies

Seventy-seven companies revealed their intent to enter the ophthalmic market in 2022, a significant increase over the 57 that announced in 2021. Market Scope categorizes them as “emerging companies...

1/24/2023
CataractIOLNewsletter
Bausch + Lomb Acquires AcuFocus, Maker of Apthera Small-Aperture IOL
Bausch + Lomb Acquires AcuFocus, Maker of Apthera Small-Aperture IOL

Bausch + Lomb reported Jan. 17 that it had acquired AcuFocus, maker of the IC-8 Apthera small-aperture intraocular lens (IOL). No financial details on the deal were provided. AcuFocus, of Irvine, C...

1/24/2023
GlaucomaNewletterPharmaRegulation
Théa Gains US FDA Approval for Iyuzeh Glaucoma Drug
Théa Gains US FDA Approval for Iyuzeh Glaucoma Drug

The US FDA has approved glaucoma drug Iyuzeh, Laboratoires Théa’s preservative-free formulation of latanoprost 0.005% for open-angle glaucoma or ocular hypertension, US subsidiary Théa Pharma annou...

1/24/2023
AcquisitionsDealsDiagnosticNewsletter
Avellino Intends to Merge with SPAC Senior Connect
Avellino Intends to Merge with SPAC Senior Connect

Privately held Avellino plans to merge with Senior Connect Acquisition Corp., a publicly traded special purpose acquisition company, Senior Connect announced Dec. 5. Scottsdale, Arizona-based Senio...

1/24/2023
FundingGene TherapyNewsletter
Perceive Bio Leads Latest Ophthalmic Fundraising with $78 Million in Series B
Perceive Bio Leads Latest Ophthalmic Fundraising with $78 Million in Series B

Retinal gene therapy developer Perceive Biotherapeutics led recent fundraising efforts by ophthalmic companies with $78 million in a Series B round. Funding announced in the past four weeks totaled...

1/24/2023
Dry EyeLaserNewsletterRegulation
Select US FDA Approvals and Clearances in December 2022
Select US FDA Approvals and Clearances in December 2022

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in December 2022, according to the agency’s database. Lutronic received clearance for an updated ve...

1/24/2023
AcquisitionsDry EyeNewsletterRegulation
2022 in Review: Surgeon and Corporate Rankings of Market Scope's Top 10 Stories for the Year
2022 in Review: Surgeon and Corporate Rankings of Market Scope's Top 10 Stories for the Year

Market Scope polled surgeons and corporate clients in January 2023 on how they would rank our selections for the top 10 stories of 2022. Their responses appear below. Alcon Makes Big Push into Phar...

1/24/2023
Dry EyeGenericsNewsletter
2022 in Review: Restasis’ Long Run of Dominance Takes Hit from US Generic
2022 in Review: Restasis’ Long Run of Dominance Takes Hit from US Generic

Allergan’s blockbuster dry eye drug Restasis finally met its match in 2022. The US FDA approved a generic version of Restasis from Viatris on Feb. 2, 2022, and the generic immediately began eating ...

1/24/2023
BiosimilarsNewsletterPharmaRetina
2022 in Review: New Entries Begin Shake-up of Retinal Pharmaceutical Market
2022 in Review: New Entries Begin Shake-up of Retinal Pharmaceutical Market

Biosimilars to established drugs for retinal diseases first became available in 2022 in the major developed markets of Europe, Japan, and the US. Senju Pharmaceuticals rolled out the first ophthalm...

1/24/2023
IndustryNewsletterPresbyopia
2022 in Review: After Big Fanfare, Has Interest in Vuity for Presbyopia Fizzled?
2022 in Review: After Big Fanfare, Has Interest in Vuity for Presbyopia Fizzled?

Vuity has been available by prescription in the US for over a year. Multiple direct-to-consumer marketing campaigns were launched following the commercial release. The ads were ubiquitous and certa...

1/24/2023
DeviceEuropeIOLNewsletterRegulation
2022 in Review: Medical Device Makers Drop Products in EU as MDR Switch Sows Chaos
2022 in Review: Medical Device Makers Drop Products in EU as MDR Switch Sows Chaos

The year closed with European Union political leaders admitting to mistakes in the union’s new medical device regulation (MDR). EU Health Commissioner Stella Kyriakides proposed in December to dela...

1/24/2023
GlaucomaNewsletterSurgical
2022 in Review: Canal-Based Procedures Expand as Option for Glaucoma Surgery
2022 in Review: Canal-Based Procedures Expand as Option for Glaucoma Surgery

Ophthalmologists performed an estimated 1.1 million glaucoma surgeries globally in 2022, with canal-based surgery the fastest-growing product segment, accounting for 228 thousand procedures, or nea...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more